Serotonergic modulation of visceral sensation: lower gut
Open Access
- 1 July 2002
- Vol. 51 (Supplement) , i81-i86
- https://doi.org/10.1136/gut.51.suppl_1.i81
Abstract
The role of 5-HT agents in the modulation of lower gastrointestinal function is discussed. Selective serotonin reuptake inhibitors are of potential benefit in functional gastrointestinal diseases although formal evidence is lacking. Novel pharmacological approaches include 5-HT3 antagonists and 5-HT4 agonists. These pharmacological classes have shown beneficial effects on a global efficacy end point, and ameliorated more than one symptom of lower gut function in clinical trials. They offer promise for the development of novel therapies for the treatment and control of irritable bowel syndrome.Keywords
This publication has 46 references indexed in Scilit:
- The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised ratGut, 2000
- Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAlimentary Pharmacology & Therapeutics, 1999
- Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic DrugClinical Pharmacokinetics, 1999
- Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteersGut, 1998
- Antidepressants for functional gastrointestinal syndromesDigestive Diseases and Sciences, 1994
- 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake.Gut, 1994
- Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.Gut, 1994
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- Effects of desipramine on irritable bowel syndrome compared with atropine and placeboDigestive Diseases and Sciences, 1987
- Irritable colon and depressionPsychosomatics, 1978